Kidney function trajectories are monitored over 2–5 year follow-up periods in active trials. Initial benefit typically manifests within 3–6 months post-infusion; plateau is reached by 12 months. Some patients sustain stable GFR for 3+ years without additional infusions; others require repeat dosing if decline resumes. Duration depends heavily on primary disease aetiology and adherence to supportive medications (ACE inhibitors, SGLT2 inhibitors, blood-pressure control).
Chronic kidney disease (CKD) reflects progressive nephron loss and functional decline, stemming from diverse primary insults (diabetes, hypertension, glomerulonephritis, polycystic kidney disease). Placental mesenchymal stem cells and their exosomes demonstrate anti-inflammatory and pro-regenerative properties relevant to CKD pathophysiology: they suppress macrophage infiltration into damaged glomeruli, inhibit fibrotic signalling pathways (TGF-β, SMAD2/3), and release growth factors that stabilise endothelial integrity. Eighty-eight registered trials and nine actively recruiting sites explore MSC infusion alongside conventional renin-angiotensin blockade and immunosuppression, particularly in early-to-intermediate stage disease where residual filtration capacity remains.
Am I a candidate? → · Chronic Kidney Disease: full overview → · Chronic Kidney Disease cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية